Craig-Hallum analyst Matt Hewitt lowered the firm’s price target on Repligen to $220 from $251 and keeps a Buy rating on the shares following quarterly results. The firm cites near-term headwinds to growth and margins, but notes the base business remains healthy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGEN:
- Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
- Repligen sees FY23 adjusted EPS $2.61-$2.69, consensus $2.92
- Repligen reports Q4 adjusted EPS 68c, consensus 58c
- Repligen CFO Snodgres sells 5,647 common shares
- Repligen appoints Martin Madaus to board of directors
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue